Get a Quote

REMDESIVIR
CAS NO.: 1809249-37-3
Chemical Formula: C27H35N6O8P
Molecular Weight: 602.6000
DMF&GMP status: Please contact us for more details.
Description:
Remdesivir is a prodrug of an adenosine triphosphate (ATP) analog, with potential antiviral activity against a variety of RNA viruses. Upon administration, remdesivir, being a prodrug, is metabolized into its active form GS-441524. As an ATP analog, GS-441524 competes with ATP for incorporation into RNA and inhibits the action of viral RNA-dependent RNA polymerase. This results in the termination of RNA transcription and decreases viral RNA production.

Remdesivir is a carboxylic ester resulting from the formal condensation of the carboxy group of N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol. A broad-spectrum antiviral prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus, MERS-CoV and SARS-CoV. It is currently in Phase III clinical trials for the treatment of Covid-19 in adults. It has a role as an antiviral drug, a prodrug and an anticoronaviral agent. It is a carboxylic ester, a pyrrolotriazine, a nitrile, a phosphoramidate ester, a C-nucleoside and an aromatic amine. It derives from a GS-441524.

Remdesivir, or GS-5734, is an adenosine triphosphate analog first described in the literature in 2016 as a potential treatment for Ebola. In 2017, its activity against the coronavirus family of viruses was also demonstrated. Remdesivir is also being researched as a potential treatment to SARS-CoV-2, the coronavirus responsible for COVID-19. Remdesivir was granted an FDA Emergency Use Authorization on 1 May 2020. This is not the same as an FDA approval.

**The products protected by patents in this product catalog are used for laboratory analysis, research and development, and cannot be sold to any country or region with patent protection and for commercial purpose. If the resulting patent infringement risks and responsibilities will be borne by the buyer.
Approvals
Active Ingredient Dosage Form; Route Strength Proprietary Name Applicant
REMDESIVIRPOWDER;INTRAVENOUS100MG/VIALREMDESIVIRGILEAD SCIENCES INC
REMDESIVIRSOLUTION;INTRAVENOUS100MG/20ML (5MG/ML)REMDESIVIRGILEAD SCIENCES INC
Patent Data
Patent No. Patent Expiration Drug Substance Claim Drug Product Claim Patent Use Code
800826409/06/2029DSDP
831868204/22/2029DSDP
972436010/29/2035DSDP
994999410/29/2035DS
1006595809/16/2031DS
1067529607/10/2038DP
1069536109/16/2036U-2984
RE4676204/22/2029DSDP
Exclusive Data
Exclusivity Code Exclusivity Expiration
NCE 10/22/2025